ST宁科董事及全体高管联合发布大规模增持计划，彰显对公司前景的坚定信心
要点总结
- 公司部分董事及全体高级管理人员将集体增持公司股票，总金额不低于370万元，最高不超过600万元。
- 所有参与增持的董事、高管目前均未直接持有公司股份，此次增持体现高管层“用真金白银”支持公司发展。
- 本次增持计划不设定价格区间，将根据市场和股价情况择机实施，计划期自2026年7月28日至2027年1月27日。
- 增持计划存在因市场、政策等不确定因素导致无法实施的风险。
- 高管承诺本次增持期间及法定期限内不会减持所持股份。
- 增持计划不会导致公司股权分布或实际控制权发生变化。
详细内容解读
宁夏中科生物科技股份有限公司（ST宁科，600165）于2026年7月25日公告，部分董事和全体高级管理人员计划于未来6个月内通过上海证券交易所集中竞价方式，合计增持公司股份金额不低于370万元、最高不超过600万元。此次增持计划反映了管理层对公司未来发展的高度认可和强烈信心，目的在于维护资本市场稳定并增强投资者信心。
值得注意的是，所有参与本次增持的董事和高管当前均未直接持有公司股份，此次为首次通过二级市场主动买入公司股票。主要参与人及增持金额区间如下：
- 董事长、总经理符杰：70万元-100万元
- 董事冯战胜：100万元-200万元
- 董事、副总经理、董事会秘书王炜：70万元-100万元
- 副总经理李忠福：70万元-100万元
- 副总经理屈晓春：30万元-50万元
- 财务总监金相宇：30万元-50万元
增持计划不设定具体价格区间，具体买入时点将依据市场和公司股价波动动态调整。所有资金来源均为高管自有或自筹资金，进一步体现其个人利益与公司发展高度绑定。
高管们承诺，在实施增持期间及法定期限内不会减持所增持股份。此外，公司明确本次增持不会导致股份分布不符合上市条件，也不会造成控股股东及实际控制人的变更。
对股东和市场的潜在影响
- 高管主动集体大额增持股份，通常被市场解读为对公司基本面和未来发展高度认可，有望提振投资者信心，进而对公司二级市场股价形成支撑和提振作用。
- 由于所有高管此前均未持股，此次“零起点”大额增持，或将被市场视为重大正面信号。
- 增持计划虽未设定价格区间，但总金额区间较大（370万-600万元），显示公司高管层与股东利益高度一致，有助于改善市场对公司治理和发展前景的预期。
- 风险提示：由于市场、政策等不确定性，增持计划可能存在延迟或无法实施的风险。公司承诺将及时履行信息披露义务。
其他说明
- 本次增持计划严格遵守《证券法》等相关法律法规。
- 公司将持续关注并及时披露增持进展，提醒广大投资者注意相关投资风险。
免责声明
本文仅为新闻报道和信息汇总，不构成任何投资建议或买卖证券的依据。投资者应根据自身判断及风险承受能力，审慎决策。公司未来业绩和股价受多重因素影响，需警惕市场不确定性风险。
English Translation
ST Ningke Directors and All Senior Management Announce Collective Share Purchase Plan, Demonstrating Strong Confidence in Company Prospects
Key Highlights
- Some directors and all senior executives plan to collectively purchase company shares, with a total amount of not less than RMB 3.7 million and no more than RMB 6 million.
- All participating directors and executives currently hold no company shares; this purchase marks their first direct investment, signaling commitment.
- The plan sets no price range; purchases will be made flexibly based on market and share price conditions, from July 28, 2026 to January 27, 2027.
- There are risks that the plan could be delayed or not executed due to market or policy changes.
- Executives commit not to sell the purchased shares during the purchase period and legal lock-up period.
- The plan will not affect the company’s shareholding structure or actual controller status.
Detailed Analysis
Ningxia Zhongke Biotechnology Co., Ltd. (ST Ningke, 600165) announced on July 25, 2026, that some directors and all senior executives plan to purchase company shares on the Shanghai Stock Exchange via centralized bidding, with a total investment of not less than RMB 3.7 million and no more than RMB 6 million over the next six months. The initiative is intended to demonstrate confidence in the company’s future, stabilize the capital market, and boost investor confidence.
Notably, all executives involved currently hold zero shares in the company, making this their first open-market purchase. The main participants and their planned investment ranges are:
- Chairman and General Manager Fu Jie: RMB 700,000–1,000,000
- Director Feng Zhansheng: RMB 1,000,000–2,000,000
- Director, Vice GM & Board Secretary Wang Wei: RMB 700,000–1,000,000
- Vice GM Li Zhongfu: RMB 700,000–1,000,000
- Vice GM Qu Xiaochun: RMB 300,000–500,000
- CFO Jin Xiangyu: RMB 300,000–500,000
No specific price range is set, and timing will depend on market and price movements. All funds are personal or self-raised by the executives, further aligning their interests with shareholders.
The executives commit not to sell the purchased shares during the plan period or statutory lock-up period. The company also confirms the plan will not result in any changes to share distribution or actual control.
Potential Impact for Shareholders and the Market
- Senior management’s substantial purchase is a strong signal of confidence and alignment with shareholders, potentially supporting and boosting the share price.
- As this is the first direct holding for the executives, the market may view this as a significant positive signal.
- The large planned amount (RMB 3.7–6 million) is meaningful in showing the executives’ commitment.
- Risk warning: Execution could be delayed or abandoned due to market or policy changes; the company will disclose any developments in a timely manner.
Additional Notes
- The plan complies with all relevant laws and regulations.
- The company will continue to disclose progress and reminds investors to be aware of risks.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should make decisions based on their own judgment and risk tolerance. Future performance and share price are subject to uncertainties.
